Meeting News

Adjuvant atezolizumab significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with resected stage II-IIIA NSCLC, according to the results of the IMpower010 study presented at 2021 ASCO Annual Meeting (Abstract 8500). 1 “IMpower010 is the first phase III study of cancer immunotherapy to demonstrate disease-free survival improvement in the adjuvant…

CT screening for lung cancer can reveal subtle early signs of disease in the lungs that extend beyond potential malignancy. As reviewed by Bram van Ginneken, PhD, of the Radboud University Medical Center in The Netherlands, quantitative measures obtained from a chest CT scan may enable the early detection of different obstructive and interstitial lung…

Although about 20% of those who die of lung cancer in the United States each year have never smoked,1 only individuals with heavy smoking histories are eligible for low-dose CT screening that can identify disease at an early stage, when curative treatment may be possible. As never-smoking populations grow in the United States and Europe,…

A wide range of nations at various stages of economic and health-system development fall under the umbrella of low- and middle-income countries (LIMC). As Lucía Viola, MD, of the Fundación Neumológica Colombiana in Bogota, Colombia, explained during a talk in which she addressed lung cancer screening implementation in these countries, LMIC “comprises regions where communicable…

Finding one effective test for the three chest conditions that are the leading causes of death in China, without a high risk of false positives, would allow better control of the mortality rate by expanding opportunities for early treatment. Researchers at three hospitals in China and one in the Netherlands are conducting the NELCIN B3…

The first forays into lung cancer screening began in the 1970s, with two trials evaluating the use of chest x-ray and sputum cytology to detect disease. Those trials showed no reductions in mortality, advocating against the practice of lung cancer screening.  In the 50 years since that time, advances in imaging, research, and clinical trials…

Even the most advanced CT scanners available face limitations in their ability to measure small lung nodules. This is a concern since small errors in two-dimensional measures can quickly balloon to become large errors in predicted volume change.  As Ricardo S. Avila, of Accumetra, LLC, explained, an axial CT image of a 6.0 by 3.6…

In his May 7 presentation “Advance Lung Cancer Screening Globally,” Dr. Pastorino, co-chair of the CT Screening Symposium and director of the Thoracic Surgery Division at the Istituto Nazionale Tumori in Milan, discussed the MILD, BioMILD, and SMILE trials. He also is chair of the IASLC’s Screening and Early Detection Committee.

Now that the positive impact of lung cancer screening on mortality and morbidity is irrefutable, there is an obvious need to find new ways to overcome consistent challenges with implementation of screening programs. It is difficult for just a single center to define and maintain logistical standards, track and improve return rates, and implement emerging…

The PARP inhibitor olaparib did not improve PFS or OS compared with placebo when used as a maintenance therapy for patients with platinum-sensitive NSCLC, according to results of the phase II PIPSeN trial.1 Sophie Postel-Vinay, MD, PhD, of the Gustave Roussy Cancer Campus in France, presented results of the trial at the European Lung Cancer…